The EdgeTRAC software Print, Apply, and Verify module from ROC IT Solutions can be used to implement serialization in manual packing operations.
The EdgeTRAC software Print, Apply, and Verify module from ROC IT Solutions is a mobile software solution that can be used in any manual packing operation. The module uses a laptop computer, handheld scanners, and mobile printers. It is designed for repackagers and low-volume manufacturers, as well as high-volume manufacturers who need to serialize a subset of their product line for export to South Korea, China, Brazil, and other countries to meet fast-approaching serialization deadlines.
Using the module on a smart handheld device, workers scan or enter a product identification for items to be labeled. Next a global trade identification number, lot, and expiry are selected, and serialized 2D-matrix barcode labels containing these standard GS1 identifiers are printed. The module supports any kind of tag format using handheld printers. After workers apply the labels and verify them with a scan from the handheld device, the ROC IT EdgeTRAC software updates all back-end systems with the commissioned serial number hierarchy data.
The module is based on GS1 standards and integrates with any EPCIS-based serial-number management system. Users can also generate and export standard reports for tag status (e.g., printed, verified, not verified, decommissioned).
Source: ROC IT Solutions
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.